The Food and Drug Administration (FDA) has approved Brexafemme for a second indication for reduction in incidence of recurrent vulvovaginal candidiasis, Scynexis announced Thursday “Brexafemme was already the…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.